In Situ Engineered “Cascade‐Amplified” Drug‐Loaded Vesicles for Enhanced Cancer Stem Cell Therapy
Journal of Extracellular Vesicles · 2026
DOI: 10.1002/jev2.70292 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Extracellular Vesicles, 2026. Verfasst von Tiantian Zhang und 11 weiteren Autor:innen. Beteiligte Einrichtung: School of Life Sciences, Zhengzhou University, Zhengzhou, Henan, China. Hauptthemen laut MEDLINE: Neoplastic Stem Cells, Doxorubicin, Extracellular Vesicles, Drug Delivery Systems. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Henan Province Natural Science Foundation, Henan Provincial Science and Technology R&D Plan Joint Foundation.
Abstract (Originalsprache)
Cancer stem cells (CSCs) characterized by the capacity of self‐renewal and drug resistance, are a major cause of tumour recurrence and metastasis. However, CSCs are mainly localized in the deep and hypoxic regions of the tumour microenvironment that hinder drug penetration. Furthermore, their overexpression of the CD24/Siglec10 immune checkpoint axis markedly suppresses immune clearance, severely limiting the efficacy of current therapeutic strategies. To address this challenge, this study developed an in situ engineered “cascade‐amplified” drug‐loaded vesicle delivery system, aiming to achieve deep drug delivery into CSC‐enriched regions and enhance anti‐tumour immune responses. Based on a biomimetic “core‐shell” nanoplatform (siXkr8/Dox@PMLC), this system initiates a cascade within the TME where Doxorubicin (Dox) induces tumour cells to generate drug‐loaded apoptotic bodies (ApoBDs). These ApoBDs serve as primary vesicles that, upon uptake by adjacent tumour cells, trigger secondary apoptosis, establishing a “cascade‐amplified” cycle of enhanced drug delivery. Meanwhile, the silencing of the phospholipid scramblase Xkr8 via siRNA inhibits phosphatidylserine (PS) exposure on the surface of ApoBDs, thereby preventing their recognition and clearance by M2‐type macrophages and facilitating immune phenotype remodelling. Furthermore, through targeted blockade of the CD24/Siglec‐10 immune axis, the nanoplatform enhances macrophage‐mediated phagocytosis of CSCs. In summary, this strategy achieves deep eradication of CSCs and synergistically enhances anti‐tumour immunotherapy, demonstrating significant translational potential.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Life Sciences, Zhengzhou University, Zhengzhou, Henan, China.
- School of Materials Science and Engineering, Zhengzhou University, Zhengzhou, Henan, China.
- Longhu Laboratory of Advanced Immunology, Zhengzhou, China.
- Institute of Aging Decoding and Regeneration, Zhengzhou University, Zhengzhou, Henan, China.
- School of Medicine, Shihezi University, Shihezi, China.
- The First Affiliated Hospital of Henan University, Kaifeng, China.
ORCID-Profile: Zhenzhen Chen
Förderung
- National Natural Science Foundation of China
- Henan Province Natural Science Foundation
- Henan Provincial Science and Technology R&D Plan Joint Foundation
- Henan Province Outstanding Youth Science Foundation
- Henan Provincial "Three 100" Program
- Zhongyuan Science and Technology Innovation Youth Top-notch Talents Project
- Natural Science Foundation of Henan Province
Zitieren
APA
Zhang, T., Wei, Y., Liu, Z., Wu, Z., Wang, X., Li, K., Liu, H., Lu, J., Lu, Q., Liu, M., Wang, Y., & Chen, Z. (2026). In Situ Engineered “Cascade‐Amplified” Drug‐Loaded Vesicles for Enhanced Cancer Stem Cell Therapy. Journal of Extracellular Vesicles. https://doi.org/10.1002/jev2.70292
Vancouver
Zhang T, Wei Y, Liu Z, Wu Z, Wang X, Li K, et al. In Situ Engineered “Cascade‐Amplified” Drug‐Loaded Vesicles for Enhanced Cancer Stem Cell Therapy. Journal of Extracellular Vesicles. 2026. doi:10.1002/jev2.70292
BibTeX
@article{Zhang2026,
author = {Zhang, Tiantian and Wei, YuanYuan and Liu, Zimai and Wu, Zixian and Wang, Xiaoxi and Li, Kai and Liu, Hui and Lu, Jiao and Lu, Qianxi and Liu, Meiyi and Wang, Yongchao and Chen, Zhenzhen},
title = {In Situ Engineered “Cascade‐Amplified” Drug‐Loaded Vesicles for Enhanced Cancer Stem Cell Therapy},
journal = {Journal of Extracellular Vesicles},
year = {2026},
doi = {10.1002/jev2.70292}
}
EUVIMED